Ulrike Lorch

1.5k total citations · 1 hit paper
58 papers, 982 citations indexed

About

Ulrike Lorch is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ulrike Lorch has authored 58 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Cardiology and Cardiovascular Medicine and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ulrike Lorch's work include Cardiac electrophysiology and arrhythmias (14 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Statistical Methods in Clinical Trials (6 papers). Ulrike Lorch is often cited by papers focused on Cardiac electrophysiology and arrhythmias (14 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Statistical Methods in Clinical Trials (6 papers). Ulrike Lorch collaborates with scholars based in United Kingdom, United States and Switzerland. Ulrike Lorch's co-authors include Jörg Täubel, Georg Ferber, Henning Weigt, Carmen Theek, Arthur A. Levin, Johann Bauersachs, Janika Viereck, Celina Genschel, Scott D. Solomon and Thomas Thum and has published in prestigious journals such as Blood, PLoS ONE and Circulation Research.

In The Last Decade

Ulrike Lorch

52 papers receiving 961 citations

Hit Papers

Novel antisense therapy targeting microRNA-132 in patient... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
    2020 266 citations Jörg Täubel, Wilfried Hauke et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ulrike Lorch United Kingdom 16 419 266 171 149 108 58 982
Nikolaos I. Vlachogiannis Greece 19 403 1.0× 135 0.5× 148 0.9× 79 0.5× 61 0.6× 47 1.0k
Weihong Sha China 17 345 0.8× 111 0.4× 133 0.8× 53 0.4× 161 1.5× 65 1.0k
Chaoyang Ye China 18 331 0.8× 73 0.3× 123 0.7× 157 1.1× 112 1.0× 61 1.1k
Roberto Vargas United States 22 344 0.8× 163 0.6× 77 0.5× 93 0.6× 288 2.7× 75 1.4k
Mulei Chen China 15 431 1.0× 259 1.0× 89 0.5× 52 0.3× 136 1.3× 63 875
Shuang Xu China 16 387 0.9× 67 0.3× 142 0.8× 40 0.3× 46 0.4× 61 828
Kenjiro Sato Japan 18 196 0.5× 186 0.7× 102 0.6× 61 0.4× 79 0.7× 48 869

Countries citing papers authored by Ulrike Lorch

Since Specialization
Citations

This map shows the geographic impact of Ulrike Lorch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Lorch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Lorch more than expected).

Fields of papers citing papers by Ulrike Lorch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Lorch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Lorch. The network helps show where Ulrike Lorch may publish in the future.

Co-authorship network of co-authors of Ulrike Lorch

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Lorch. A scholar is included among the top collaborators of Ulrike Lorch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Lorch. Ulrike Lorch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saultier, Paul, Laurent Frenzel, Roger E. G. Schutgens, et al.. (2025). Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study. Blood. 146(Supplement 1). 842–842.
2.
3.
Kuemmerle, Andrea, et al.. (2024). Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin. Clinical and Translational Science. 17(4). e13738–e13738. 2 indexed citations
4.
Baker, Teresa, Ulrike Lorch, Yu Z. Bagger, et al.. (2024). No Measurable Transfer of Oxytocin-Receptor Agonist Merotocin Detected in Human Breast Milk. Breastfeeding Medicine. 19(6). 451–458.
5.
Täubel, Jörg, et al.. (2023). The Reliability of Auto-Injectors in Clinical Use: A Systematic Review. Cureus. 15(7). e41601–e41601. 4 indexed citations
6.
Bush, James, et al.. (2023). Association for Human Pharmacology in the Pharmaceutical Industry conference 2022: impending change, innovations and future challenges. Frontiers in Pharmacology. 14. 1219591–1219591. 1 indexed citations
7.
Täubel, Jörg, et al.. (2021). Concentration‐QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. British Journal of Clinical Pharmacology. 88(1). 128–137. 4 indexed citations
8.
Täubel, Jörg, Wilfried Hauke, Steffen Rump, et al.. (2020). Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European Heart Journal. 42(2). 178–188. 266 indexed citations breakdown →
9.
Albayaty, Muna, James Bush, Joseph Cheriyan, et al.. (2020). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. Frontiers in Pharmacology. 11. 580560–580560.
10.
11.
Mundin, Gill, et al.. (2018). Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study. European Journal of Drug Metabolism and Pharmacokinetics. 44(1). 63–75. 7 indexed citations
12.
Reijntjes, Susan, Muna Albayaty, James Bush, et al.. (2018). The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. Frontiers in Pharmacology. 9. 1301–1301. 1 indexed citations
13.
Täubel, Jörg, et al.. (2018). Practical risk management in early phase clinical trials. European Journal of Clinical Pharmacology. 75(4). 483–496. 6 indexed citations
14.
McDonald, Rebecca, et al.. (2017). Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction. 113(3). 484–493. 62 indexed citations
15.
Elks, Cathy E., Paul Martin, David Carlile, et al.. (2017). Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology. 73(6). 717–726. 12 indexed citations
16.
17.
Wang, Duolao, et al.. (2011). Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. The Journal of Clinical Pharmacology. 52(9). 1441–1447. 30 indexed citations
18.
Lorch, Ulrike, et al.. (2011). The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings. European Journal of Clinical Pharmacology. 68(5). 543–551. 10 indexed citations
19.
Dixon, Ruth, Sarah A. Job, Ruth Oliver, et al.. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology. 66(3). 396–404. 82 indexed citations
20.
Dettmar, Peter W., et al.. (2007). The suppression of gastro-oesophageal reflux by alginates. International Journal of Clinical Practice. 61(10). 1654–1662. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikolaos I. Vlachogiannis Breakdown of academic impact, for papers by Weihong Sha Breakdown of academic impact, for papers by Chaoyang Ye Breakdown of academic impact, for papers by Roberto Vargas Breakdown of academic impact, for papers by Mulei Chen Breakdown of academic impact, for papers by Shuang Xu Breakdown of academic impact, for papers by Kenjiro Sato
Rankless by CCL
2026